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Abstract
Background:  Basic and clinical research suggests a potential role for repetitive transcranial
magnetic stimulation (rTMS) in the treatment of Parkinson's disease. However, compared to the
growing number of clinical studies on its putative therapeutic properties, the studies on the basic
mechanisms of rTMS are surprisingly scarce.
Results: Animal studies have broadened our understanding of how rTMS affects brain circuits and
the causal chain in brain-behavior relationships. The observed changes are thought to be to
neurotransmitter release, transsynaptic efficiency, signaling pathways and gene transcription.
Furthermore, recent studies suggest that rTMS induces neurogenesis, neuronal viability and
secretion of neuroprotective molecules.
Conclusion: The mechanisms underlying the disease-modifying effects of these and related rTMS
in animals are the principle subject of the current review. The possible applications for treatment
of Parkinson's disease are discussed.
Background
The clinical motor dysfunction in Parkinson's disease
(PD) is primarily the consequence of a progressive degen-
eration of dopaminergic neurons in the substantia nigra
of the nigrostriatal pathway. The degeneration of this tract
provokes a depletion of dopamine in the striatum, where
it is required for normal motor function [1]. Restoring
dopamine levels with L-dopa is still the most widely used
treatment of PD. However, despite conflicting data, L-
dopa is suspected to exert neurotoxic properties that can
accelerate the loss of dopaminergic neurons [2]. In addi-
tion, it elicits marked dyskinesias, and its therapeutic effi-
cacy gradually wanes over years of exposure [2]. Although
the dopamine precursor is effective in the short-term in
relieving motor dysfunction, it does not stop the progres-
sive disappearance of dopaminergic neurons, encouraging
interest in alternative therapeutic strategies [2,3].
Recent studies suggest a potential role of repetitive tran-
scranial magnetic stimulation (rTMS) in different neu-
ropsychiatric diseases and have been used to investigate
almost all areas of cognitive neuroscience [for review see
refs [4,5]. The use of rTMS in clinical neurophysiological
studies is highly advanced and has been reviewed else-
where [which can be found in refs [5-8]]. rTMS is a non-
invasive brain stimulation technique that can produce
lasting changes in excitability and activity in cortical
regions underneath the stimulation coil (local effect), but
also within functionally connected cortical or subcortical
regions (remote effects) [4-8]. Since the clinical presenta-
tion of PD is related to abnormal neuronal activity within
the basal ganglia and cortical regions, including the pri-
mary motor cortex, the premotor cortex and the prefrontal
cortex [1], several studies have used rTMS to improve
brain function in PD [6,7]. The basic mechanisms of rTMS
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in the context of pathophysiology of PD are the principle
subject of the current review.
rTMS as a technique for noninvasive stimulation of the 
human brain
Electromagnetic induction was described by Michael Far-
aday. This principle, formulated mathematically by James
C. Maxwell, states that fluctuating magnetic fields can
induce electric current in conductors placed nearby.
Recently, this principle has been applied to induce electric
current in the adult human brain, in a technique known
as transcranial magnetic stimulation (TMS) [for review see
refs [4,5]]. A variant of TMS, in which the stimulus can be
repeated for a few seconds at frequencies up to 50 Hz, is
referred to as rTMS [4-6]. rTMS is an experimental tool for
stimulating neurons via brief magnetic pulses delivered by
a coil placed on the scalp. rTMS can non-invasively inter-
fere with neural functions related to a target cortical area
with high temporal accuracy [4-6]. The key features of the
technique are that rTMS machine delivers a large current
in a short period of time – the current in the rTMS coil
then produces a magnetic field which, if changing rapidly
enough, will induce an electric field sufficient to stimulate
neurons or change the resting membrane potential in the
underlying cortex [4-8]. In short, rTMS can be used to
induce a transient interruption of normal brain activity in
a relatively restricted area of the brain [4-8]. Because of
these unique and powerful features, rTMS has been popu-
lar in various fields, including cognitive neuroscience and
clinical application [for review see refs [4-7]]. However,
despite its utility, the mechanisms of how rTMS stimulates
neurons and interferes with neural functions are still
unknown.
Cellular and molecular mechanisms of rTMS
Animal studies have broadened our understanding of
how rTMS affects brain functioning (Fig. 1). There is evi-
dence that rTMS causes changes in neuronal circuits as
reflected by behavioral changes [4-8]. These alterations
include regional changes in the release of neurotransmit-
ters, transsynaptic efficiency, signaling pathways and in
gene transcription.
A possible mechanism by which rTMS exerts and effect is
through gene induction [8-10]. Different studies support
that rTMS modulates the expression of immediate early
genes such as c-fos and c-jun [8-10]. These genes are acti-
vated transiently and rapidly in response to a wide variety
of cellular stimuli. They represent a standing response
mechanism that is activated at the transcription level in
the first round of response to stimuli, before any new pro-
teins are synthesized [8-10]. A single rTMS train increased
c-fos mRNA in the paraventricular nucleus of the thala-
mus, and to a lesser extent in the frontal and cingulate cor-
tices, but not in the parietal cortex [9]. In contrast to these
acute effects, 14 daily rTMS treatments increased c-fos
mRNA in the parietal cortex [10]. No change was seen in
Brain-derived neurotrophic factor (BDNF) mRNA expres-
sion [10]. Another study found that a longer treatment (5-
day series separated by 2-day intervals for 11 weeks) sig-
nificantly enhanced BDNF mRNA in the hippocampus
and the parietal and piriform cortices [11]. The BDNF is
the most abundant and widely distributed neurotrophin
in the CNS and plays regulatory roles in many neuronal
functions including survival, neurogenesis, and synaptic
plasticity. Effects on neurotrophic factors could possibly
explain preliminary findings of neuroprotective and neu-
roplastic effects of rTMS, such as mossy fiber sprouting in
the hippocampus following chronic rTMS [12]. Possible
effects of rTMS on neurotrophic factors might be relevant
to new theories about the mechanisms of action of antide-
pressant medications [13].
Importantly, specific effects of rTMS on neurotransmitter
system have been repeatedly reported. Acute treatment
with rTMS in rodents modulates monoamine content and
turnover [14,15], but no effects on neurotransmitter levels
or metabolites have been reported after chronic stimula-
tion [16]. Shortly after rTMS, dopamine is reported to be
reduced in the frontal cortex and increased in the striatum
[14] and the hippocampus [14,15]. Increased serotonin
(5-HT) in the hippocampus was found in brain homoge-
nates with HPLC [14], but not in an in vivo microdialysis
study [15]. Reductions in arginine vasopressin release and
increases in taurine, aspartate, and serine were reported in
the hypothalamic paraventricular nucleus with rTMS [15].
The dopaminergic system might therefore be one of the
primary candidate neurotransmitter systems which are
directly and selectively modulated by rTMS of frontal
brain regions. It ventral tegmental area (VTA) and the sub-
stantia nigra, i.e. the regions of origin of the mesolimbic
and mesostriatal dopaminergic pathways [17]. These neu-
roanatomical connections may explain how stimulation
of frontal brain regions enhances dopamine efflux in axon
terminal areas originating from mesencephalic dopamin-
ergic cell groups. Apart from the hippocampus, the ventral
(i.e. nucleus accumbens) and dorsal striatum receive
dense dopaminergic projections from the VTA and sub-
stantia nigra respectively, [18,19] and therefore might be
candidate regions for possible rTMS-induced changes in
interneuronal communication. Consistent with the
hypothesis that stimulation of frontal brain regions by
rTMS may increase dopaminergic neurotransmission in
areas other than the hippocampus, it has been reported
that direct electrical stimulation of the prefrontal cortex
enhances dopamine release in the dorsal striatum and
nucleus accumbens [20,21].International Archives of Medicine 2008, 1:2 http://www.intarchmed.com/content/1/1/2
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The neurochemical changes induced by the exposure to
rTMS in vivo are preserved and expressed in the tissue in
vitro. rTMS initiates the biosynthesis of new molecules
which persist in the tissue beyond the period of stimula-
tion [22,23]. The activation of a rat's brain with rTMS
enhanced the magnitude of long-term potentiation (LTP)
recorded in vitro [24] and made the hippocampal slices
prepared from exposed brains much more resistant to
ischemic damage [25,26]. This data suggest a protective
effect of BDNF for synaptic transmission after transient
forebrain ischemia.
Given the beneficial effects of rTMS in the treatment of
affective disorders, the mesolimbic dopaminergic system
is of particular interest as it comprises the major compo-
nents of the neural circuitry of reward and incentive moti-
vation [27]. With respect to PD, activation of the
mesostriatal dopaminergic pathway is likely to be a possi-
ble candidate mechanism behind the therapeutic effects
of rTMS that have been reported [28-30].
Several studies in humans have shown that acute and
chronic rTMS treatments of the frontal cortex improve the
symptoms of PD, which is thought to result from subcor-
tical dopamine dysfunction [31]. Interestingly, acute
rTMS treatment of the prefrontal cortex (PFC) in humans
was demonstrated by functional neuroimaging to induce
a release of endogenous dopamine in the ipsilateral dorsal
striatum [32]. Animal studies have shown that descending
pathways from the frontal cortex modulate dopamine
Repetitive transcranial magnetic stimulation (rTMS) is a technique for noninvasive stimulation of the adult brain Figure 1
Repetitive transcranial magnetic stimulation (rTMS) is a technique for noninvasive stimulation of the adult 
brain. Stimulation is produced by generating a brief, high-intensity magnetic field by passing a brief electric current through a 
magnetic coil. Compared with the growing number of clinical trial with rTMS, there are surprisingly few animal studies on its 
basic mechanisms of action, constraining the ability to perform hypothesis-driven clinical studies.International Archives of Medicine 2008, 1:2 http://www.intarchmed.com/content/1/1/2
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release in subcortical areas, such as the striatum [33].
Modulation of dopamine release may be relevant to the
pathophysiology of PD [31].
Neurogenesis in the adult brain
The dogma that the adult mammalian brain is incapable
of cellular self-repair has finally been overcome, when the
generation of new neurons in the adult brain was
described for the subventricular zone (SVZ) as well as for
the dentate gyrus subgranular zone (SGZ) of the hippoc-
ampus [3,34-36] (Fig. 2A). The SVZ is an important germi-
nal layer that forms during development adjacent to the
telencephalic ventricular zone. This layer is most promi-
nent in the lateral wall of the lateral ventricle facing the
developing ganglionic eminences. The SVZ contains the
largest pool of dividing neural progenitors/stem cells
(NSCs) in the adult brain of all mammals, including
humans [3,34-36]. In rodents, the adult SVZ contains four
cell types defined by their morphology, ultrastructure,
molecular markers and electrophysiological properties: 1)
migrating neuronal progenitor cells (type A cells), 2) SVZ
protoplasmic astrocytes (type B cells), 3) transit amplify-
ing progenitor cells (type C cells), and 4) ependymal cells
(type E cells) that separated the SVZ from the ventricular
cavity, whose function is to circulate the cerebrospinal
fluid (Fig. 2B) [3,34-36]. The organization of the adult
human SVZ is significantly different compared to that of
rodents (Fig. 2C). In adult rodents, SVZ astrocytes (Type B
cells) are located next to the ependymal layer. In contrast,
in the adult human brain, SVZ astrocytes are not found
adjacent to the ependymal cells (Fig. 2D). Instead, the cell
bodies of human SVZ astrocytes accumulate in a band or
ribbon separated from the ependymal layer by a gap that
is largely devoid of cells [37].
Different growth/trophic factor and cytokines have been
identified in vivo as modulators of the numeric expansion
and as fate determinants of NSCs, such as epidermal
growth factor (EGF), transforming growth factor α (TGF-
α), fibroblast growth factor (FGF-2), nerve growth factor
(NGF), BDNF, glial cell line-derived neurotrophic factor
(GDNF), basic fibroblast growth factor (bFGF), insulin-
like growth factor-1 (IGF-1), erythropoietin (EPO) and
others [3,34-36]. These agents, however, appear to act
solely as mitogens without changing the fate determina-
tion of the NSCs and their progeny.
Studies in various animal disease models have convinc-
ingly shown that the SVZ can respond to insults in the
adult brain by producing new progenitor cells that can
migrate to sites that have been affected by neurodegener-
ative pathology or brain injury [3,36]. In response to neu-
rodegeneration in Huntington's disease, epilepsy,
multiple sclerosis and stroke, there is an upregulation of
progenitor cell production, cytokine levels and migratory
proteins in the SVZ, leading to an increase in the number
of adult-born neurons. By contrast, in Alzheimer's disease
and PD there are fewer proliferating cells in the SVZ
[3,36].
Neurogenesis and rTMS
With regard to the development of a cell replacement ther-
apy in PD, it is intriguing to know that dopaminergic neu-
rons are constitutively regenerated by adult neurogenesis
in the olfactory bulb of the adult brain [3,34-37]. These
neurons are born in the SVZ and migrate via the rostral
migratory stream to the olfactory bulb, where they inte-
grate as interneurons in the glomerular layer [3,34-37]. A
detailed understanding of the molecular signals govern-
ing the proliferation, targeted migration and dopaminer-
gic differentiation of these precursor cells may offer the
exciting perspective that the endogenous NSCs in the SVZ
may ultimately be instrumentalized for non-invasive
replacement of the degenerating nigrostriatal system by
autologous dopaminergic neurons [3].
Dopaminergic innervation and signalling in the SVZ pro-
foundly increases the SVZ's proliferative capacity. A recent
study used a 6-hydroxidopamine (6-OHDA) lesion model
of PD, in which the medial forebrain bundle (also know
as the nigrostriatal pathway) is destroyed by an excito-
toxin, and measured proliferation in the SVZ [38] (Fig.
3A). The number of proliferating cells was found to have
decreased by approximately 40%, as measured by bromo-
deoxyuridine (BrdU)-positive cells counts. Furthermore,
this study demonstrated that the amount of proliferation
in the SVZ after a 6-OHDA lesion was proportional to the
amount or remaining dopaminergic innervation in the
striatum [38]. After the dopamine precursor L-DOPA was
administered, normal proliferation levels were restored in
the side ipsilateral to the lesion, however, on the contral-
ateral side, L-DOPA had no effect [38]. In a hypothesis-
based attempt to identify such factors, intrastriatal infu-
sion of TGFα in a rodent model of PD has been shown to
induce massive proliferation and migration of cells from
the SVZ toward the TGFα infusion site [39]. This treat-
ment has been reported to result in increased numbers of
dopaminergic-like neurons in the striatum. In behavioral
experiments, there was a significant reduction of apomor-
phine-induced rotations in animals receiving the TGFα.
However, a more recent attempt to replicate this finding
has reproduced the precursor cell immigration, but failed
to show a neuronal phenotype of the newborn striatal
cells [40]. In this later study, intrastriatal TGFα infusion
induced a significant increase in SVZ proliferation and
substantial migratory waves of nestin-positive progenitor
cells from the adult SVZ into the striatum of dopamine-
depleted rats, but there was no dopaminergic differentia-
tion of the newborn neurons [40]. In a similar way, infu-
sion of BDNF into the lateral ventricle of the adult rat hasInternational Archives of Medicine 2008, 1:2 http://www.intarchmed.com/content/1/1/2
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been reported to induce migration of SVZ-derived neu-
roblasts into the parenchyma of the striatum [41].
In sharp contrast, there appears to be a reduction in pre-
cursor cell proliferation in the SVZ of PD patients and
experimental animals as a consequence of dopamine
depletion [3,38]. Recent studies have suggested that 60
daily rTMS treatments (60 Hz, 0.7 mT; Fig. 1) induce an in
situ  differentiation of SVZ-derived precursors in
dopamine-producing neurons in rats with unilateral 6-
OHDA lesions of the substantia nigra (Fig. 3) [42,43]. In
behavioral experiments, there was a significant reduction
of amphetamine-induced rotations in animals receiving
the rTMS. The number of new dopaminergic cells was cor-
related with better locomotor activity (Fig. 3B). Patch-
clamp studies suggested that a small percentage of SVZ-
derived dopaminergic-like cells exhibited the electrophys-
iological properties of mature dopaminergic neurons and
presented spontaneous postsynaptic potentials [43]. Fur-
ther work is required to identify the key molecular players
The anatomy of the neurogenic subventricular zone in the adult rodent and human brain Figure 2
The anatomy of the neurogenic subventricular zone in the adult rodent and human brain. (A) Sagittal view of a 
rodent brain showing the sites of neurogenesis in the subventricular zone/olfactory bulb (SVZ/OB) system. (B) Schematic 
drawing of the composition and cytoarchitecture of the adult rodent SVZ. (C) Coronal view of the adult human brain showing 
the basal ganglia and lateral ventricles. (D) Schematic drawing depicting the cellular composition and cytoarchitecture of the 
adult human SVZ, consisting of four layers: Layer I – ependymal cell layer (green), Layer II – hypocellular gap, Layer III – astro-
cytic ribbon, containing astrocytes and migrating neuroblasts, Layer IV – transitional zone, containing oligodendrocytes and 
separating the SVZ from the striatum rich in neurons. RMS: rostral migratory stream; DG: dentate gyrus; LV: lateral ventricle.International Archives of Medicine 2008, 1:2 http://www.intarchmed.com/content/1/1/2
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regulating this phenomenon, in order to develop novel
cell therapies for PD based on rTMS.
On the other hand, it has been demonstrated that cerebral
ischemia increases neurogenesis both in the SGZ and in
the SVZ of the adult brain [44-46]. This increase has been
associated with the activation of the NMDA receptor [47].
The neuronal precursors of the SVZ migrate to the
ischemic zone of the adjacent striatum [45,46] and
through the rostral migratory stream (RMS) and the lat-
eral cortical stream to the ischemic zone of the cerebral
cortex where the damaged neurons are differentiated and
replaced [44-46]. Clinical trials using low-frequency rTMS
applied to the unaffected hemisphere demonstrated
decreased interhemispheric inhibition of the affected
hemisphere with the associated behavioral changes in
stroke patients [48,49]. Despite there being clinical evi-
dence suggesting that electrical cortical DC stimulation to
the affected hemisphere1 and low frequency rTMS to the
unaffected hemisphere can modulate the cortical excita-
bility and produce measurable hand motor improvement
in stroke patients, the efficacy of high-frequency rTMS on
the corticomotor excitability and the acquisition of motor
skills in chronic stroke patients is being explored [48-50].
Although the effect of rTMS on neurogenesis in post-
stroke  is not known, it is a study that should be explored.
Conclusion
To date, experimental evidences suggest that rTMS induces
changes in neurotransmitter release, transsynaptic effi-
ciency, signaling pathways and gene transcription. Fur-
thermore, recent studies suggest that rTMS induces
neurogenesis, neuronal viability and secretion of neuro-
protective molecules in an animal model of PD. rTMS rep-
resents a new strategy to regenerate the CNS enhancing
neurogenesis in adults. A detailed understanding of the
factors governing adult neurogenesis in vivo may ulti-
mately lead to elegant cell therapies for PD and other neu-
rodegenerative disorders by mobilizing endogenous NSCs
to replace degenerated neurons. Finally, we must remem-
ber that however exciting the neurobiological mecha-
nisms might be, the clinical usefulness of rTMS will be
determined by their ability to provide patients with neu-
rological disorders with safe, long-lasting and substantial
improvements in quality of life.
Neurogenesis and rTMS Figure 3
Neurogenesis and rTMS. (A) Dopaminergic neurons reside in the substantia nigra pars compacta (SNc), which is located in 
the ventral midbrain, and send axonal projections to the striatum, which is situated in the forebrain. Neural stem cells are 
located in the adult SVZ, immediately adjacent to the striatum, with is rich in dopaminergic afferents from the SNc. In the 6-
OHDA animal model of Parkinson's disease, the nigral dopaminergic neurons are destroyed unilaterally by means of a stereo-
tactic injection of the toxin, as indicated by the needle. The consecutive depletion of dopamine (DA↓) in the striatum leads to 
a decreased proliferation of progenitor cells in the SVZ. (B) In rats with unilateral 6-OHDA lesion of the SNc, rTMS induces an 
in situ differentiation of SVZ-derived precursors in dopamine-producing neurons. Some nucleus marked with BrdU (green) 
colocalize with the cytoplasmatic TH (red). OB: olfactory bulb; V: ventricle; VZ: ventricular zone.International Archives of Medicine 2008, 1:2 http://www.intarchmed.com/content/1/1/2
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